Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment (2022 - 2025)

Recursion Pharmaceuticals (RXRX) has 4 years of Asset Writedowns and Impairment data on file, last reported at $6.0 million in Q1 2025.

• Quarterly Asset Writedowns and Impairment rose 5414.81% year-over-year to $6.0 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $6.0 million (up 5414.81% YoY) and the FY2025 annual result came in at $6.0 million, up 5414.81% from the prior year.
• Asset Writedowns and Impairment rose to $6.0 million in Q1 2025, from $108000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $6.0 million in Q1 2025 to a low of $19000.0 in Q3 2023.
• A 4-year average of $2.0 million and a median of $1.2 million in 2023 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment plunged 90.76% — and 2025, when it soared 5414.81%.
• Tracing RXRX's Asset Writedowns and Impairment over 4 years: stood at $2.8 million in 2022, then sank by 99.32% to $19000.0 in 2023, then surged by 468.42% to $108000.0 in 2024, then surged by 5414.81% to $6.0 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $6.0 million (Q1 2025), $108000.0 (Q1 2024), and $19000.0 (Q3 2023), per Business Quant data.